Skip to content

Understanding patients with elevated pulmonary arterial pressure

Phenotyping individuals with elevated mean pulmonary arterial pressure and elevated pulmonary vascular resistance in the United Kingdom

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN34481181
Enrollment
2000
Registered
2021-06-09
Start date
2009-01-01
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension Circulatory System Pulmonary hypertension

Interventions

This retrospective, observational, multi-center study aims to describe patient and clinical characteristics, biomarkers, therapies, and prognosis of patients categorized into 3 groups based on their M

Sponsors

Royal Free London NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged =18 years at time of the first right heart catheter (RHC) procedure within the eligibility period 2. =1 RHC procedure in one of the pulmonary hypertension specialist or approved centers within the eligibility period

Exclusion criteria

Exclusion criteria: 1. Missing value for mean Pulmonary Arterial Pressure or Pulmonary Vascular Resistance at the right heart catheter (RHC) procedure 2. Received any Pulmonary arterial hypertension medications before the first RHC procedure 3. Lung and/or heart transplant any time before the first RHC procedure 4. Enrolled in any interventional clinical trial with an investigational product within the 3 months prior to, or at the time of, the first RHC procedure within the eligibility period

Design outcomes

Primary

MeasureTime frame
1. Hospitalization measured using the incidence of inpatient hospitalization events due to any cause anytime during the observation period (01/01/2009 to 01/03/2020) from retrospective HES and ONS or ISD data collection at a single timepoint 2. Mortality rates measured using the time to all-cause mortality anytime during the observation period (01/01/2009 to 01/03/2020) from retrospective HES and ONS or ISD data collection at a single timepoint

Secondary

MeasureTime frame
1. Quality of life measured using the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) or emPHasis-10 questionnaire anytime during the observation period (01/01/2009 to 01/03/2020) from retrospective HES and ONS or ISD data collection at a single timepoint 2. Progression to Pulmonary Hypertension measured using the date of Right Heart Catheterisation (RHC) anytime during the observation period (01/01/2009 to 01/03/2020) when the measured mPAP is =25 mmHg for the first time after the index RHC from retrospective HES and ONS or ISD data collection at a single timepoint

Countries

England, Scotland, United Kingdom

Contacts

Public ContactIvy Wanjiku Dakouri
ivy.wanjiku@nhs.net+44 (0)2073177544

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 27, 2026